Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2

The European Respiratory Journal
M HumbertG Simonneau

Abstract

The efficacy and safety of combining bosentan, an orally active dual endothelin receptor antagonist and epoprostenol, a continuously infused prostaglandin, in the treatment of pulmonary arterial hypertension (PAH) was investigated. In this double-blind, placebo-controlled prospective study, 33 patients with PAH started epoprostenol treatment (2 ng.kg(-1)min(-1) starting dose, up to 14+/-2 ng.kg(-1)min(-1) at week 16) and were randomised for 16 weeks in a 2:1 ratio to bosentan (62.5 mg b.i.d for 4 weeks then 125 mg b.i.d) or placebo. Haemodynamics, exercise capacity and functional class improved in both groups at week 16. In the combination treatment group, there was a trend for a greater (although nonsignificant) improvement in all measured haemodynamic parameters. There were four withdrawals in the bosentan/epoprostenol group (two deaths due to cardiopulmonary failure, one clinical worsening, and one adverse event) and one withdrawal in the placebo/epoprostenol group (adverse event). This study showed a trend but no statistical significance towards haemodynamics or clinical improvement due to the combination of bosentan and epoprostenol therapy in patients with pulmonary arterial hypertension. Several cases of early and late m...Continue Reading

Citations

Sep 27, 2012·Rheumatology International·Afsha A Topal, Rachita S Dhurat
Aug 19, 2011·General Thoracic and Cardiovascular Surgery·Kengo F Kusano
Feb 21, 2009·Current Atherosclerosis Reports·Aydin Uzunpinar, Mehmet Cilingiroglu
May 4, 2005·Current Cardiology Reports·Mohammed Najeeb Osman, Mark E Dunlap
Oct 15, 2013·Current Hypertension Reports·Yan WuMarc Humbert
Jul 24, 2008·Current Treatment Options in Cardiovascular Medicine·Jennifer Cowger MatthewsKeith D Aaronson
Jan 10, 2009·Clinical Reviews in Allergy & Immunology·Vasiliki Kalliopi K BourniaM Eric Gershwin
Apr 2, 2011·Advances in Therapy·Jean-Luc Vachiéry
Nov 16, 2011·Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·E S Hoendermis
May 27, 2006·Cardiology in the Young·Eugene KotlyarDavid S Celermajer
May 25, 2007·Nature Clinical Practice. Cardiovascular Medicine·Aniket PuriSudhir S Kushwaha
Apr 14, 2010·Nature Reviews. Rheumatology·Manuel Ramos-CasalsAntoni Sisó-Almirall
Sep 17, 2013·Seminars in Respiratory and Critical Care Medicine·Shinichi Takatsuki, David Dunbar Ivy
Aug 30, 2013·The New England Journal of Medicine·Tomás PulidoUNKNOWN SERAPHIN Investigators
Oct 2, 2004·The New England Journal of Medicine·Marc HumbertGérald Simonneau
Jan 22, 2009·European Heart Journal·Nazzareno GalièAngelo Branzi
Apr 17, 2010·Cardiology in Review·Joe R Anderson, James J Nawarskas
Jul 31, 2008·Current Opinion in Pulmonary Medicine·David PolomisKeith C Meyer
Mar 20, 2010·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·D Dunbar Ivy
Sep 25, 2008·Respirology : Official Journal of the Asian Pacific Society of Respirology·Daniele BendayanMordechai R Kramer
Oct 27, 2006·Heart·Astrid E LammersSheila G Haworth
Sep 24, 2011·Pulmonary Medicine·Jeanne HoutchensJames R Klinger
Sep 2, 2006·American Journal of Respiratory and Critical Care Medicine·Vallerie V McLaughlinLewis J Rubin
Mar 5, 2008·American Journal of Respiratory and Critical Care Medicine·Marc Humbert
Jun 23, 2012·American Journal of Respiratory and Critical Care Medicine·Stephen C MathaiRobert A Wise
Sep 4, 2012·American Journal of Respiratory and Critical Care Medicine·Lewis J Rubin
Feb 2, 2010·Respiratory Research·Christopher J RyersonDon D Sin
Jun 4, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Bing HeHongfang Jin
Jul 16, 2010·Circulation Journal : Official Journal of the Japanese Circulation Society·Yutaka MiuraHiroaki Shimokawa
May 1, 2005·Future Cardiology·Steeve ProvencherOlivier Sitbon
Nov 19, 2009·Drug Design, Development and Therapy·Brian Casserly, James R Klinger
Nov 19, 2009·Drug Design, Development and Therapy·Kari E Roberts, Ioana R Preston
Jun 26, 2009·Vascular Health and Risk Management·Amy Hawkins, Robert Tulloh
Aug 19, 2009·Vascular Health and Risk Management·Christopher J Valerio, John G Coghlan
Oct 7, 2010·Clinical Drug Investigation·Zeenat Safdar
Dec 23, 2010·Future Cardiology·Nathan Dwyer, David Kilpatrick
Jan 10, 2008·Annals of Cardiac Anaesthesia·Shahzad G Raja, Gilles D Dreyfus
Jul 1, 2005·Future Cardiology·Lewis J RubinMichael J Gerber
Oct 12, 2013·Paediatric Drugs·Erika E Vorhies, David Dunbar Ivy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

American Journal of Respiratory and Critical Care Medicine
V McLaughlinL J Rubin
The New England Journal of Medicine
N GalieSildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group
The New England Journal of Medicine
Horst OlschewskiAerosolized Iloprost Randomized Study Group
© 2021 Meta ULC. All rights reserved